Replies to post #121523 on Biotech Values

[DewDiligence]

MNTA—I am not sure I agree with your characterization of "legacy business" that Wheeler was talking about.

I’m very, very sure that legacy business in this context used on the GS webcast refers to prospective partners’ traditional branded biologics, not to their biosimilars.

If you don’t want to take my word for it, call MNTA and ask.